CK supports suspicion but does not define the mutation. Diagnosis and treatment eligibility depend on a clinical evaluation plus a clearly interpreted DMD-gene report; ask for genetic counseling and a copy of the report.
What this means in real life
Creatine kinase, usually written CK, is an enzyme that leaks from damaged muscle. A very high CK can strongly support suspicion of a muscular dystrophy, but CK cannot identify the DMD mutation, distinguish every Duchenne/Becker situation or determine treatment eligibility. CK can also be elevated for other reasons, so it is evidence—not the complete diagnosis.
Genetic testing looks for a disease-causing change in the DMD gene. Many first-line tests detect exon deletions or duplications; sequencing is often used when those tests are negative or incomplete. The report should state the exact variant, its classification and the method used. If the result is a variant of uncertain significance, or if the genetic result does not fit the clinical picture, the team may recommend expert reinterpretation, additional testing or occasionally muscle studies.
Keep the original report because mutation-specific medicines and trials use exact wording. “Deletion around exon 51” is not precise enough to determine exon-skipping amenability. A genetic counselor or Duchenne specialist should interpret the report against the current drug label.
A practical checklist
- ✓
Get the complete laboratory report, including methodology and variant classification.
- ✓
Confirm whether deletion/duplication analysis and sequencing were both addressed.
- ✓
Ask genetics to write the exact mutation in plain language.
- ✓
Do not use CK level to judge day-to-day progression or treatment response unless the team specifically explains why.
- ✓
Request re-review when the result is uncertain or conflicts with symptoms.
Questions to bring with you
Use these at the clinic, school meeting, equipment evaluation, program interview or benefits call. Write down the answers and who owns the next step.
- Is this variant pathogenic, likely pathogenic or uncertain?
- Was the test capable of finding small sequence changes as well as deletions and duplications?
- Does the result predict Duchenne, Becker or another dystrophinopathy with confidence?
- Is the mutation amenable to any currently approved mutation-specific therapy?
- Who should receive targeted family testing?
Important context
Individual needs, eligibility and safety can differ. Confirm the plan with the relevant Duchenne-experienced clinician, therapist, school team or program before acting.
Sources used for this guide
Direct links are included so families can check the original guidance and bring it to qualified professionals.
Content review: July 18, 2026. Medical labels, trials, benefits and programs can change after publication.
Did this article answer the question?
A thumbs-down sends the article to the private administrator dashboard for review.